Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and tolerability of ALKS 5461 as adjunctive therapy for major depressive disorder
2014-000380-41Phase 3Completed
- Sponsor
- Alkermes
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of buprenorphine + samidorphan in major depressive disorder (MDD), sponsored by Alkermes. Primary endpoint: Safety and tolerability (adverse events). Started Jul 2014; status: completed.
02
Drugs
buprenorphine + samidorphan
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2014-000380-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000380-41.